HHS Urges Faster GLP-1 R&D Amid Unusual Side Effects Concerns | Retatrutide News

The HHS is calling for faster R&D in GLP-1 agonists like Retatrutide due to unusual side effects. Eli Lilly's metabolic pipeline could be impacted by th...
Market News · October 10, 2026